Sarepta touts Duchenne gene therapy uptake, but warns of demand flattening before potential expanded label from FDA
Sarepta Therapeutics announced Wednesday afternoon that its Duchenne muscular dystrophy gene therapy Elevidys pulled in $200 million in its first half-year on the commercial market.
In the fourth quarter of 2023, the gene therapy’s sales jumped to $131.2 million, up from $69 million in the first few months it was on the market. All in all, the biotech eclipsed $1 billion in sales in 2023 on all its Duchenne medicines, which include three “exon-skipping” drugs in addition to the gene therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.